Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).

被引：5

作者：

Bauman, Julie E.

Saba, Nabil F.

Roe, Denise

Bauman, Jessica R.

Kaczmar, John M.

Bhatia, Aarti K.

Muzaffar, Jameel

Julian, Ricklie Ann

Wang, Steven

Bearelly, Shethal

Baker, Audrey

Steuer, Conor Ernst

Giri, Anshu

Burtness, Barbara

Centuori, Sara

Caulin, Carlos

Saboda, Kathylynn

Obara, Stefanie

Chung, Christine H.

机构：

[1] Univ Arizona, Canc Ctr, Dept Med, Div Hematol Oncol, Tucson, AZ USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Univ Arizona, Tucson, AZ USA

[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[5] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA

[6] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] NYU, Sch Med, New York, NY USA

[9] Univ Arizona, Canc Ctr, Tucson, AZ USA

[10] Yale Sch Med, New Haven, CT USA

[11] Yale Canc Ctr, New Haven, CT USA

来源：

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.6015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6015

引用

页数：3